| Name | Title | Contact Details |
|---|---|---|
Scott Yarman |
Chief Information Officer | Profile |
Stephen Agar |
VP, IT Infrastructure, Operations and Cybersecurity (CISO) | Profile |
John Kish |
Chief Information Officer | Profile |
Bio-Tec Emergency Svc is a Lindstrom, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Southern Regional Medical Center (SRMC) is a 331-bed hospital serving Riverdale, Georgia, and the surrounding communities. The hospital is owned by Prime Healthcare, an award winning health system that owns nearly 50 hospitals in 14 states.
Swisher Hygiene is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Charlotte, NC. To find more information about Swisher Hygiene, please visit www.swisherhygiene.com
Recuro is a leading virtual-first care delivery company offering a personalized, holistic, and proactive approach to healthcare, looking to make advanced healthcare more accessible. Recuro provides seamless access to various virtual care services, including primary and urgent care, behavioral health, at-home lab testing, and genomics testing. Additionally, Recuro provides a comprehensive suite of supplemental benefits, integrated prescriptions, care management, and care navigation, all available on a unified platform.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.